OncoGenex Announces Results from the Phase 3 AFFINITY Trial of Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer
Across tumor types, the majority of patients with cancer are likely to face treatment resistance at some point.Learn More
OncoGenex does not review the information contained on the following Web site for content, accuracy or completeness. Use of and access to the information are subject to the terms, limitations and conditions set by the Web site producer. OncoGenex makes no claims about the accuracy or any other aspect of the information contained on this Web site, nor does OncoGenex necessarily endorse this Web site.